Chronopin: upcoming release dates, events and other important dates

Separate construction cost, IT power, floor area and an opening date for this building or phase have not been verified. Published campus figures do not establish independent component figures.

Separate construction cost, IT power, floor area and an opening date for this building or phase have not been verified. Published campus figures do not establish independent component figures.

GSK's phase 3 trial of MRNA Seasonal Flu Vaccine in influenza, human reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 54,000 participants. This study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season. The study will measure prevention of laboratory-confirmed flu illness, side effects, and immune responses.

The United Kingdom and Ireland co-host the European Championship across nine stadiums. Estimated date.

Amgen's phase 3 trial of Maridebart Cafraglutide in atherosclerotic cardiovascular disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 12,800 participants. The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Amgen's phase 3 trial of Maridebart Cafraglutide in heart failure with preserved ejection fraction reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,056 participants. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

On 27 October 2026 Kalshi put an official Bloomberg IPO confirmation at 3.5% before Jan 1, 2027, rising to 50% before Jan 1, 2030. The largest step in the ladder runs from Jul 1, 2028 to Jan 1, 2029 (24% to 35%), so that window is the market's most likely stretch; it is a bet on timing, not a listing date.